Karyopharm Therapeutics (NASDAQ:KPTI) Raised to Buy at StockNews.com

Karyopharm Therapeutics (NASDAQ:KPTI) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Thursday.

A number of other brokerages have also recently commented on KPTI. Royal Bank of Canada reaffirmed an “outperform” rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. Piper Sandler upped their price objective on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Robert W. Baird reduced their target price on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Finally, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a research note on Friday, November 1st. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $5.00.

Karyopharm Therapeutics Stock Performance

Shares of NASDAQ:KPTI opened at $0.81 on Thursday. Karyopharm Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $1.95. The company’s 50-day moving average is $0.82 and its 200 day moving average is $0.90. The company has a market capitalization of $102.01 million, a P/E ratio of -0.71 and a beta of 0.16.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Tuesday, November 5th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. The company had revenue of $38.78 million for the quarter, compared to the consensus estimate of $37.86 million. During the same period in the prior year, the company earned ($0.30) earnings per share. As a group, research analysts predict that Karyopharm Therapeutics will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

A number of large investors have recently modified their holdings of KPTI. FMR LLC boosted its stake in Karyopharm Therapeutics by 26.1% during the third quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after buying an additional 76,510 shares during the period. GSA Capital Partners LLP raised its holdings in shares of Karyopharm Therapeutics by 80.6% in the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock valued at $1,474,000 after acquiring an additional 792,283 shares in the last quarter. Exchange Traded Concepts LLC grew its holdings in shares of Karyopharm Therapeutics by 34.9% during the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock worth $182,000 after purchasing an additional 56,613 shares in the last quarter. Point72 DIFC Ltd bought a new position in shares of Karyopharm Therapeutics in the second quarter worth approximately $31,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in Karyopharm Therapeutics in the second quarter valued at approximately $494,000. 66.44% of the stock is currently owned by institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).